To test whether the observed NVP-2 antitumor effects translated to HCC tumors harboring other genetic lesions, we performed similar treatment studies in mice harboring HCC tumors driven by MYC overexpression and Axin1 deletion, another common event in human HCCs that also drives tumorigenesis in the HTVI system (37). The gene discussed is MYC; the disease is hepatocellular carcinoma.